VALBIOTIS
30.9.2020 17:42:03 CEST | Business Wire | Press release
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces its results for the first half of 2020 and provides an update on developments since the beginning of the year.
Sébastien PELTIER, CEO of VALBIOTIS, commented: "Events in the first half of 2020 have transformed our outlook and helped further boost our international recognition. With the signature of the development and marketing partnership for TOTUM-63 and the launch of the final clinical phase for this Nutrition Healthcare product, entirely financed by Nestlé Health Science, we have demonstrated the soundness of our development model. We are now moving confidently towards marketing and claim submission for TOTUM-63 and, thanks to a solid financial position, we are also working to apply this same model to the rest of our Nutrition Healthcare portfolio. At the head of the pipeline is TOTUM-070, which has just obtained U.S. and European patents, required to establish a commercial partnership in the future. We still have work to do with this product and our other ongoing developments, but the road ahead is now clear!"
Key achievements since the beginning of 2020
TOTUM-63, prediabetes
- Signature of a global strategic partnership with Nestlé Health Science
At the beginning of fiscal year 2020, VALBIOTIS announced the signature of a global strategic partnership with Nestlé Health Science for the development and marketing of TOTUM-63, a plant-based active substance clinically proven to have metabolic benefits in prediabetics just six months earlier (press release of February 5, 2020 ).
This strategic partnership guarantees the financing of TOTUM-63's late-stage clinical development until the health claims are obtained from the American and European authorities. In addition to milestone payments and royalties expected from marketing, this agreement also includes an additional source of revenue: the supply of TOTUM-63 by VALBIOTIS to Nestlé Health Science.
- Launch of REVERSE-IT, the last phase of clinical development, and inclusion of the first patient
Following the conclusion of this agreement and with the favorable opinion of the CPP (French Committee for the Protection of Persons) and the authorization of the ANSM (French National Agency for the Safety of Medicines and Health Products), VALBIOTIS announced the launch of REVERSE-IT, the last phase of clinical development for TOTUM-63 (press release of July 8, 2020 ).
REVERSE-IT, fully funded by Nestlé Health Science, will include 600 people recruited in more than 30 international clinical centers. The main objective of the study is to confirm the positive Phase II results already obtained with TOTUM-63 on fasting blood glucose, a risk factor for type 2 diabetes.
The COVID-19 public health and economic crisis has not impacted VALBIOTIS' business plan, which had anticipated the production of clinical batches for REVERSE-IT. As a result, the first visit of the first patient in the REVERSE-IT clinical study was carried out as announced in mid-2020 (press release of July 15, 2020 ). The results of this study are expected in the first half of 2022 and will allow, in the event of positive results, the filing of a health claim application with the American and European authorities.
- Cumulative payments since the signature of the partnership: CHF 8M
With this major agreement, in April VALBIOTIS received a first payment (upfront) from Nestlé Health Science for an amount of CHF 5M. The partnership also includes milestone payments (up to CHF 66M), such as the CHF 3M payment validated by Nestlé Health Science for the inclusion of the first patient in July, received in September 2020.
As a reminder, TOTUM-63 may be marketed before health claims are obtained. The negotiated agreement also includes progressive royalties on net sales.
TOTUM-070, reduction of LDL hypercholesterolemia ("bad cholesterol")
- Launch of the Phase II clinical study in the second half of 2020
On the strength of this major success, VALBIOTIS confirmed the continuation of its well-established development strategy. As a consequence, the Company announced the development of three innovative Nutrition Healthcare active substances from its proprietary R&D platform, also targeting the early stages of chronic metabolic and cardiovascular diseases with unmet medical needs.
The first active substance being developed is TOTUM-070 for the reduction of blood LDL cholesterol levels, a risk factor for cardiovascular disease (press release of April 16, 2020 ). A Phase II clinical study is planned to start in the second half of 2020 and will evaluate the effect of TOTUM-070 on the reduction of LDL-cholesterol in individuals with mild to moderate hypercholesterolemia. The results of this study are expected by the end of fiscal year 2021/early 2022. This research program is supported by a €500K grant awarded by the European Regional Development Fund (ERDF) of the Nouvelle Aquitaine region.
VALBIOTIS plans to obtain, notably in Europe and North America, the first proprietary health claim relating to the reduction of LDL cholesterol, a risk factor for cardiovascular disease, for a product containing neither phytosterols nor red rice yeast.
- Obtaining an American and European patent
VALBIOTIS has taken a key step in the development of its active substance TOTUM-070 with the granting of its US and European patent (press release of September 14, 2020 ). This protects the composition of TOTUM-070 for food and pharmaceutical applications in strategic international markets.
It is estimated that in 2020, more than 174 million adults in the United States and Europe will be living with hypercholesterolemia, and the market for non-prescription products is estimated at €1.2 billion in these regions1 .
TOTUM-854, blood pressure reduction, and TOTUM-448, liver steatosis reduction: clinical development programs in progress
In line with its roadmap, VALBIOTIS has also made progress on two other Nutrition Healthcare development programs (press release of April 16, 2020 ). These two active substances are now ready to enter Phase II of clinical development with:
- The initiation of a Phase II clinical study in the first quarter of 2021 evaluating the effect of TOTUM-854 on the reduction of blood pressure, a risk factor for cardiovascular disease, in patients with mild to moderate hypertension, and;
- The launch of a Phase II clinical study in the second half of 2021 evaluating the effect of TOTUM-448 on the reduction of liver steatosis, a condition that increases the risk of developing NASH, in patients with non-alcoholic fatty liver (NAFL).
Major scientific recognition
During fiscal year 2020, VALBIOTIS has intensified its scientific promotion strategy for its clinical results.
VALBIOTIS was selected by the American Diabetes Association (ADA) to present Phase II clinical results for TOTUM-63 demonstrating the metabolic benefits of its Nutrition Healthcare active substance in prediabetic subjects (press release of June 12, 2020 ). This fourth publication at the world's largest diabetes congress is a sign of strong recognition by the scientific community.
A few months later, VALBIOTIS was selected for the third consecutive year by the European Association for the Study of Diabetes (EASD) to present its results on TOTUM-63 (press release of September 21, 2020 ). This new selection by the leading European diabetes congress is further testimony to the value of these clinical results.
These publications at the two largest world diabetes congresses highlights the quality of VALBIOTIS' research programs and its innovative approach, to the main scientific and industrial players in the field of Nutrition Healthcare.
Financial information for the first half of 2020: a solid financial situation
The Company's interim financial statements, prepared in accordance with IFRS, were approved by the Executive Board on September 24, 2020. They have been subject to a limited review by the Statutory Auditors and are available on the VALBIOTIS website: www.valbiotis.com
IFRS in €K(1) , at June 30 |
S1 2020 |
S1 2019 |
Operating revenue, of which |
714 |
1,023 |
Turnover |
121* |
46 |
Grants |
156 |
372 |
Research tax credit |
437 |
605 |
R&D expenses |
(1,939) |
(2,105) |
Sales and Marketing expenses |
(545) |
(823) |
Overheads |
(638) |
(641) |
Current operating result |
(2,557) |
(2,639) |
Operating result |
(2,557) |
(2,639) |
Pre-tax profit or loss |
(2,830) |
(2,724) |
Net result |
(2,931) |
(2,724) |
|
||
IFRS in €K(1) |
S1 2020 |
S1 2019 |
Cash flow generated by activity |
3,323 |
(3,139) |
Cash flow linked to investments |
(101) |
(54) |
Cash flow linked to financing activities |
(341) |
(330) |
Net cash flow |
2,881 |
(3,523) |
Balance |
10,914 |
3,897 |
*For the first half of 2020, VALBIOTIS generated turnover of €121K, resulting from recognition of the initial payment of CHF 5M received by the Company in April 2020. This initial payment, acquired from the date of signature, is considered to be part of the service price and is therefore spread over the duration of the contract, i.e. until October 2035.
Operating income therefore amounted to €714K, mainly consisting of research tax credits, turnover and state subsidies.
In the first half of the year, Research and Development expenses decreased by 8% compared to the same period last year, to €1,939K. This evolution is mainly due to the absence of clinical studies carried out during the period, which was focused on the preparation of the launch of REVERSE-IT and the continuation of preclinical research work on the technical platform in Riom. Sales and Marketing expenses were also down 34% compared to the first half of 2019, at €545K. This decrease in business development efforts follows the effective signature of the contract with Nestlé Health Science. Finally, overheads expenses remained stable at €638K in S1 2020 compared to €642K in S1 2019. Overall, VALBIOTIS recorded a net loss of €2,931K.
For the first half of the year, cash flow generated by activity was positive at €3,323K, driven by the CHF 5M upfront payment from Nestlé Health Science. Cash flow linked to investments was negative by €101K, mainly related to activities aimed at extending VALBIOTIS' intellectual property rights with the registration of trademarks and patents internationally. Finally, cash flow linked to financing activities was negative by €341K, largely due to the restatement of lease contracts in the context of the implementation of IFRS 16.
At June 30, 2020, VALBIOTIS had a cash position of €10,914K, up 36% compared to December 31, 2019.
To date, and taking into account in particular:
- €10,914K of available cash as at June 30, 2020
- Operating expenses related to the current development plan;
- The maturity schedule of the current financial debt;
- Receipt in the second half of 2020 of the CHF 3M milestone payment resulting from the partnership signed with Nestlé Health Science;
- The capital increase of €2M carried out in July 2020;
- Receipt in the summer of 2020 of €3M from the French State-guaranteed loan (PGE) obtained from the banking consortium made up of Bpifrance, Société Générale and BNP Paribas;
The Company has carried out a specific review of its liquidity and considers that it does not face any short-term risk. As of today, the end of cash flow is estimated to be in the first half of 2022.
On the basis of the current development plan, this timeframe could be extended if additional revenues are generated to complement the milestone payments already scheduled with Nestlé Health Science. This scenario may arise in particular in the event that TOTUM-63 is marketed before the health claim is obtained, which would result in the early payment of progressive royalties on net sales. The communicated cash horizon also does not include revenues from new strategic partnerships that may be entered into for other products in the current portfolio.
VALBIOTIS' half-year financial report at June 30, 2020 has been made available to the public and filed with the French financial markets regulator (AMF). This document can be consulted on the website: valbiotis.com ("Investors" section).
ABOUT VALBIOTIS
VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health world.
VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63).
VALBIOTIS is a member of the “BPI Excellence” network and received “Innovative Company“ status awarded by BPI France. VALBIOTIS has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.
Find out more about VALBIOTIS: www.valbiotis.com
Name: VALBIOTIS
ISIN code: FR0013254851
Mnemonic code: ALVAL
DISCLAIMER
This press release contains forward-looking statements about VALBIOTIS’ objectives, based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the VALBIOTIS registration document, filed with the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 120--018). This document is available on the Company’s website (www.valbiotis.com ).
This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS’ shares or securities in any country.
1 AEC Partners data for the United States and VALBIOTIS' 5 priority European countries (Germany, Spain, France, Italy and the United Kingdom), 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200930005626/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 17:00:00 CET | Press release
Canada becomes the 25th Allied nation to back the NATO Innovation Fund, gaining access to €1.1 billion in mission-aligned capital and a co-investor network spanning the Alliance Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the amb
Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 15:30:00 CET | Press release
Independent evaluation of Persona's Android SDK confirms defenses against deepfakes and other injected media at the top level of the first standard Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result
Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release
Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release
With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
